Bangalore, March 26, 2008: Siro Clinpharm, one of India’s full service clinical research organization (CRO) has appointed Ajit Nair as president of its India business. He will hold overall responsibility of business in India, and will be responsible for the massive expansion in operational scale and technology that are currently underway in Siro.

 

Before Siro, Nair was in a senior leadership role at Glenmark Pharmaceuticals, a top Indian pharma company. Dr. Nair’s responsibilities included clinical development of New Chemical Entities (NCE), global CRO management encompassing clinical operations, clinical data management & biometrics and drug safety for clinical studies outsourced.

 

“We are thrilled to have someone with Ajit’s background and experience as a part of our leadership team,” said Dr. Chetan Tamhankar, COO of Siro Clinpharm. “His understanding of the complexities of clinical research in India will provide further confidence to the growing list of MNC pharmaceutical and biotech clientele that utilize Siro’s India services."

 

This is Dr. Nair’s second stint with Siro. His return is the third in a series of high profile returns to SIRO from pharmaceutical companies. Before Glenmark, Dr. Nair served in challenging positions in Clinical Research Operations/Medical Services with Novartis and Wockhardt. Dr. Nair has a PhD in Pharmacology from Mumbai University.